DEBRISOQUINE HYDROXYLATION CAPACITY: PROBLEMS OF ASSESSMENT IN TWO POPULATIONSINABA T; OTTON SV; KALOW W et al.1981; CLIN. PHARMACOL. THER.; ISSN 0009-9236; USA; DA. 1981; VOL. 29; NO 2; PP. 218-223; BIBL. 17 REF.Article

UN NOUVEL ANTIHYPERTENSEUR SYMPATHOPLEGIQUE: LE SULFATE DE DEBRISOQUINEBIRON P.1973; UN. MED. CANADA; CANADA; DA. 1973; VOL. 102; NO 5; PP. 1134-1135; ABS. ANGL.; BIBL. 16REF.Serial Issue

TOLERANCE AND SIDE EFFECTS DURING LONG TERM TREATMENT OF HYPERTENSION WITH DEBRISOQUINE = TOLERANCE ET EFFETS SECONDAIRES AU COURS DU TRAITEMENT PROLONGE DE L'HYPERTENSION PAR LA DEBRISOQUINEJACKSON WB.1972; AUSTRAL. NEW ZEAL. J. MED.; AUSTRAL.; DA. 1972; VOL. 2; NO 4; PP. 357-365; BIBL. 9 REF.Serial Issue

IN VITRO METABOLISM OF SPARTEINE BY HUMAN LIVER; COMPETITIVE INHIBITION BY DEBRISOQUINEOTTON SV; INABA T; MAHON WA et al.1982; CAN. J. PHYSIOL. PHARMACOL.; ISSN 0008-4212; CAN; DA. 1982; VOL. 60; NO 1; PP. 102-105; BIBL. 11 REF.Article

Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in SwedenAKLILLU, Eleni; HERRLIN, Karin; GUSTAFSSON, Lars L et al.Pharmacogenetics (London). 2002, Vol 12, Num 5, pp 375-383, issn 0960-314XArticle

RADIOIMMUNOASSAY OF THE ANTI-HYPERTENSIVE AGENT DEBRISOQUIN.DIXON R; FAHRENHOLTZ KE; BURGER W et al.1977; RES. COMMUNIC. CHEM. PATHOL. PHARMACOL.; U.S.A.; DA. 1977; VOL. 16; NO 1; PP. 121-129; BIBL. 1 P.Article

COMPARISON OF DEBRISOQUINE AND GUANETHIDINE IN TREATMENT OF HYPERTENSION = COMPARAISON DES TRAITEMENTS A LA DEBRISOQUINE ET A LA GUANETHIDINE DANS L'HYPERTENSIONADI FC; EZE CJ; ANWUNAH A et al.1975; BRIT. MED. J.; G.B.; DA. 1975; NO 5956; PP. 482-485; BIBL. 3REF.Article

DER SUBMAXIMALE ERGOMETRISCHE BELASTUNGSVERSUCH BEI HYPERTONIKERN UNTER BEWEGUNGSTHERAPIE UND BEHANDLUNG MIT DEBRISOQUIN. = EPREUVE D'EFFORT EN ERGOMETRIE SUBMAXIMALE CHEZ DES PATIENTS HYPERTENDUS EN PHYSIOTHERAPIE, ET TRAITEMENT PAR DEBRISOQUINEPOZENEL H.1975; WIEN. KLIN. WSCHR.; DTSCH.; DA. 1975; VOL. 87; NO 22; PP. 767-772; ABS. ANGL.; BIBL. 24 REF.Article

THE METABOLISM OF (¹⁴C)-DEBRISOQUINE IN MANIDLE JR; MAHGOUB A; ANGELO MM et al.1979; BRIT. J. CLIN. PHARMACOL.; GBR; DA. 1979; VOL. 7; NO 3; PP. 257-266; BIBL. 30 REF.Article

ACTION ANTIHYPERTENSIVE DE LA DEBRISOQUINEPERRET L.1975; PRAXIS; SCHWEIZ; DA. 1975; VOL. 64; NO 21; PP. 653-659; ABS. ANGL.; BIBL. 22REF.Article

ETUDES THERAPEUTIQUES FAITES AVEC LE TENDOR (SULFATE DE DEBRISOQUINE)LANGER L; GERO A.1974; THERAP. HUNGAR.; HONGR.; DA. 1974; VOL. 22; NO 4; PP. 177-184; BIBL. 13REF.Article

Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expressionSCHULZ-UTERMOEHL, T; BENNETT, A. J; ELLIS, S. W et al.Pharmacogenetics (London). 1999, Vol 9, Num 3, pp 357-366, issn 0960-314XArticle

The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populationsBAPIRO, Tashinga E; HASLER, Julia A; RIDDERSTRÖM, Marianne et al.Biochemical pharmacology. 2002, Vol 64, Num 9, pp 1387-1398, issn 0006-2952, 12 p.Article

A human cytochrome P-450 characterized by inhibition studies at the sparteine―debrisoquine monooxygenaseINABA, T; NAKANO, M; OTTON, S. V et al.Canadian journal of physiology and pharmacology. 1984, Vol 62, Num 7, pp 86-862, issn 0008-4212Article

A POPULATION AND FAMILIAL STUDY OF THE DEFECTIVE ALICYCLIC HYDROXYLATION OF DEBRISOQUINE AMONG EGYPTIANSMAHGOUB A; IDLE JR; SMITH RL et al.1979; XENOBIOTICA; GBR; DA. 1979; VOL. 9; NO 1; PP. 51-56; BIBL. 8 REF.Article

POLYMORPHISM OF CARBON OXIDATION OF DRUGS AND CLINICAL IMPLICATIONSSLOAN TP; MAHGOUB A; LANCASTER R et al.1978; BRIT. MED. J.; GBR; DA. 1978; NO 6138; PP. 655-657; BIBL. 15 REF.Article

New allelic arrangement CYP2D6*36×2 found in a Japanese poor metabolizer of debrisoquineCHIDA, Michihiro; ARIYOSHI, Noritaka; YOKOI, Tsuyoshi et al.Pharmacogenetics (London). 2002, Vol 12, Num 8, pp 659-662, issn 0960-314X, 4 p.Article

DEBRISAN IN THE LOCAL TREATMENT OF INFECTED AND BURN WOUNDSANGORN IB.1982; CURR. THER. RES.; ISSN 0011-393X; USA; DA. 1982; VOL. 31; NO 2; PP. 148-152; BIBL. 4 REF.Article

CATECHOLAMINE METABOLITES IN HUMAN PLASMA AS INDICES OF BRAIN FUNCTION: EFFECTS OF DEBRISOQUINSWANN AC; MAAS JW; HATTOX SE et al.1980; LIFE SCI. (1973); ISSN 0024-3205; GBR; DA. 1980; VOL. 27; NO 20; PP. 1857-1862; BIBL. 28 REF.Article

INFLUENCE OF THE GENETICALLY CONTROLLED DEFICIENCY IN DEBRISOQUINE HYDROXYLATION ON ANTIPYRINE METABOLITE FORMATIONDANHOF M; IDLE JR; TEUNISSEN MWE et al.1981; PHARMACOLOGY; ISSN 0031-7012; CHE; DA. 1981; VOL. 22; NO 6; PP. 349-358; BIBL. 2 P.Article

POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN.MAHGOUB A; ILDE JR; DRING LG et al.1977; LANCET; G.B.; DA. 1977; NO 8038; PP. 584-586; BIBL. 7 REF.Article

METABOLISM OF DEBRISOQUINE SULFATE. IDENTIFICATION OF SOME URINARY METABOLITES IN RAT AND MAN.ALLEN JG; EAST PB; FRANCIS RJ et al.1975; DRUG METABOL. DISPOSIT.; U.S.A.; DA. 1975; VOL. 3; NO 5; PP. 332-337; BIBL. 6 REF.Article

DRUG INTERACTIONS IN PATIENTS ON LONG-TERM ORAL ANTICOAGULANT AND ANTIHYPERTENSIVE ADRENERGIC NEURON-BLOCKING DRUGS = INTERACTIONS MEDICAMENTEUSES CHEZ DES MALADES TRAITES A LONG TERME PAR DES ANTICOAGULANTS ORAUX ET PAR DES BLOQUANTS ADRENERGIQUES ANTIHYPERTENSEURSSTARR KJ; PETRIE JC.1972; BRIT. MED. J.; G.B.; DA. 1972; NO 5833; PP. 133-135; BIBL. 12 REF.Serial Issue

POLYMORPHIC OXIDATION OF SPARTEINE AND DEBRISOQUINE: RELATED PHARMACOGENETIC ENTITIESEICHELBAUM M; BERTILSSON L; SAWE DJ et al.1982; CLIN. PHARMACOL. THER.; ISSN 0009-9236; USA; DA. 1982; VOL. 31; NO 2; PP. 184-186; BIBL. 14 REF.Article

METABOLISM OF DEBRISOQUINE SULPHATE IN RAT, DOG AND MANALLEN JG; BROWN AN; MARTEN TR et al.1976; XENOBIOTICA; G.B.; DA. 1976; VOL. 6; NO 7; PP. 405-409; BIBL. 1 REF.Article